- NxStage names Joseph Turk President, North America
NxStage Medical, Inc. (NSDQ:NXTM), a leading manufacturer of innovative dialysis products, today announced that Joseph E. Turk, Jr., has been promoted to the position of President of its North American operations. Reporting to Jeffrey Burbank, Chief Executive Officer of NxStage, Mr. Turk will continue to manage the Company’s North American commercial teams across the Company’s three markets (Home, Critical Care, and In-Center) and will be responsible for driving NxStage’s worldwide product portfolio.
- Cook Incorporated Names Rob Dorocke Vice President, Global e-Communications
Rob Dorocke, who has served as the company’s global e-communications director since 2006, has been promoted to vice president of global e-communications, Cook Inc. officials said today. In his new role, Dorocke will lead Cook’s online and digital efforts, including social media tools, to help educate physicians and patients worldwide about the benefits of Cook Medical technologies.
- LDR Spine Welcomes Mr. Joe Ross as Vice President of U.S. Marketing
LDR, a total solution spine company, announced today that Mr. Joe Ross has joined the company as Vice President of U.S. Marketing. In this new role, which strengthens the U.S. organization for LDR Spine, Mr. Ross will lead all aspects of commercial marketing and provide essential support for continued sales growth.
- Aperio Names Patrick Yount as Chief Financial Officer
Aperio, the global leader in providing digital pathology solutions to improve patient care, has appointed Patrick Yount, a veteran of the healthcare industry, as its chief financial officer. Yount’s addition to Aperio directly supports the company’s mission to improve patient care in healthcare and life sciences organizations through its digital pathology solutions.
- ERT Announces the Appointment of Joel Morganroth, MD as Interim CEO
ERT (NSDQ:ERES), a global provider of technology and services to the pharmaceutical, biotechnology and medical device industries, today confirmed that the effective date of the previously announced retirement of Dr. Michael J. McKelvey, its President and CEO, is December 21, 2010.
- Sysmex America Announces Executive Promotions
Sysmex, a global leader in medical diagnostic testing equipment and information systems technology, today announced two organizational changes that further position the company’s North American subsidiary for continued growth and market leadership. John Kershaw, President & CEO, Sysmex America, Inc. has promoted Ralph Taylor to the role of Executive Vice President, Marketing, Business Development and Medical/Scientific Affairs and Robert Degnan to Executive Vice President, Commercial Operations both effective today. Each will report directly to the President & CEO. Sysmex America is the U.S. headquarters for Sysmex Corporation, Kobe, Japan and has oversight of the corporation’s subsidiaries in Canada and Latin America.
- Boston Scientific Announces Election of Dr. Kristina M. Johnson to its Board of Directors
Boston Scientific Corporation (NYSE:BSX) today announced that the Company’s Board of Directors has elected Kristina M. Johnson, Ph.D., as a Director, effective January 1, 2011. Dr. Johnson previously served as a Director of Boston Scientific before accepting an appointment in 2009 as Under Secretary at the U.S. Department of Energy.
- AcuMEMS Appoints Richard M. Ferrari to Board
AcuMEMS, Inc. today announced the appointment of Richard M. Ferrari as a new member of its Board of Directors.
- Endologix Appoints Guido Neels to Its Board of Directors
Endologix, Inc. (NSDQ:ELGX), developer of minimally invasive treatments for aortic disorders, announced today that Guido Neels, Managing Director at Essex Woodlands Health Ventures, has joined the Endologix Board of Directors. Essex Woodlands was the majority shareholder of Nellix Inc, which was acquired by Endologix in an all stock transaction on December 13, 2010. In conjunction with the acquisition, Essex Woodlands made a $15 million equity investment in Endologix. Endologix now has five independent directors and three non-independent directors.